


Amundi

# Amundi S&P World Health Care Screened ETF Acc

IE0006FM6MI8

28-05-2026

FM



## Investment objective

## Fees

|                           |   |
|---------------------------|---|
| Entry fee                 | -->Tarievenkaart / Cost information sheet |
| Exit charges              | -->Tarievenkaart / Cost information sheet |
| Estimated ongoing charges | 0,18%                                     |

## Dividend

|                 |    |
|-----------------|----|
| Dividend paying | No |
|-----------------|----|

## Quote

|            |            |
|------------|------------|
| Quote      | €10,87     |
| Quote date | 27-05-2026 |

## Performance in EUR

|                          |            |
|--------------------------|------------|
| Date                     | 27-05-2026 |
| This year                | -4,25%     |
| 1 week                   | 0,84%      |
| 1 month                  | 3,91%      |
| 3 months                 | -5,84%     |
| 6 months                 | -6,35%     |
| 1 year                   | 6,70%      |
| 3 years (annualised)     | 2,48%      |
| 5 years (annualised)     | -          |
| Since start (annualised) | 2,19%      |

## Indicators

|                          |        |
|--------------------------|--------|
| Standard deviation (3yr) | 13,00% |
| Share ratio (3yr)        | -0,03  |
| Beta (3yr)               | 1,02   |
| Alpha (3yr)              | -0,50  |
| Tracking error (3yr)     | 2,65   |


## Top 10 holdings (30-04-2026)

|                                      |         |
|--------------------------------------|---------|
| Eli Lilly and Co                     | 11,25 % |
| AbbVie Inc                           | 7,00 %  |
| UnitedHealth Group Inc               | 6,31 %  |
| AstraZeneca PLC                      | 4,78 %  |
| Merck & Co Inc                       | 4,59 %  |
| Roche Holding AG Ordinary Shares new | 4,39 %  |
| Novartis AG Registered Shares        | 4,20 %  |
| Amgen Inc                            | 3,23 %  |
| Thermo Fisher Scientific Inc         | 3,15 %  |
| Gilead Sciences Inc                  | 2,67 %  |

?>

## Characteristic

|                             |  |
|-----------------------------|--|
| Asset Manager               | Amundi   |
| Asset class                 | Equities   |
| Investment category         | Equities - Healthcare                                    |
| Active/Passive              | Passive  |
| Fund code                   | 206360   |
| Fund code fractional orders | -  |
| Fund manager name           | Quentin Berrou Shan Zhao Arnaud Vergonjeanne             |
| ISIN                        | IE0006FM6MI8   |
| Sustainable Classification  | Art. 8, ESG integration                                  |
| Sustainability Rating       |  |
| Domicile                    | Ireland  |
| Currency                    | EUR  |
| Fund size (mio)             | €365,37 (27-05-2026)                                     |
| Cut-off time                | -  |
| Execution date              | niet van toepassing:<br>directe verhandeling op de beurs |
| Inception date              | 20-09-2022   |
| Benchmark                   | S&P World Health Care Wghtd & Scr TR USD                 |
| Minimum investment amount   | -  |
| Assortiment                 | Self Directed Investing Plus, Investment advice          |



**General Disclaimer**

The information provided in this document has been drafted by ABN AMRO Bank N.V

**About ABN AMRO**

ABN AMRO Bank N.V. has its registered office at Gustav Mahlerlaan 10, 1082 PP Amsterdam (the Netherlands). Telephone: 0900 - 0024\*. Internet: abnamro.nl ABN AMRO Bank N.V. holds a banking licence from De Nederlandsche Bank N.V. (the Dutch central bank) and is included in the register of the Autoriteit Financiële Markten (AFM - Authority for the Financial Markets) under number 12000004. ABN AMRO Bank N.V. is entered in the Trade Register of the Amsterdam Chamber of Commerce under number 34334259. The VAT identification number of ABN AMRO Bank N.V. is NL8206.46.660B01.

**US Securities Law Disclaimer**

ABN AMRO Bank N.V. ('ABN AMRO') is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the '1934 Act') and under applicable state laws in the United States. In addition, ABN AMRO is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the 'Advisers Act' and together with the 1934 Act, the 'Acts'), and under applicable state laws in the United States. Accordingly, absent specific exemption under the Acts, any brokerage and investment advisory services provided by ABN AMRO, including (without limitation) the investment products and investment services described herein are not intended for U.S. persons. Neither this document, nor any copy thereof may be sent to or taken into the United States or distributed in the United States or to a US person. Without limiting the generality of the foregoing, the offering, sale and/or distribution of the investment products or investment services described herein is not intended in any jurisdiction to any person to whom it is unlawful to make such an offer, sale and/or distribution. Persons into whose possession this document or any copy thereof may come, must inform themselves about, and observe, any legal restrictions on the distribution of this document and the offering, sale and/or distribution of the investment products and investment services described herein. ABN AMRO cannot be held responsible for any damages or losses that occur from transactions and/or services in defiance with the restrictions aforementioned.

\* Call charges: for this call you pay your usual call charges set by your telephone provider